US FDA’s Stein ‘Excited’ About Real-World Evidence, Rare Disease Endpoint Pilot Programs

 
• By Brenda Sandburg
  
Excited
FDA official is enthusiastic about agency's new pilot programs • Source: Alamy

More from User Fees

More from Pathways & Standards